Atlas Trials

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

Clinical trial NCT02515227 · COMPLETED

Trial details

NCT number
NCT02515227
Sponsor
Craig L Slingluff, Jr
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Melanoma
Start date
2016-10-06
Primary completion
2020-03-14
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.